Abstract: A gene encoding human glycosyltransferase (human GnT-III) and recombinant DNA method for producing the enzyme are provided. A cancerous metastasis inhibitor comprising GnT-III, or a gene thereof, and a method of inhibiting cancerous metastasis in a mammal are also provided.

Abstract: A gene encoding human glycosyltransferase (human GnT-III) and recombinant DNA method for producing the enzyme are provided. A cancerous metastasis inhibitor comprising GnT-III, or a gene thereof, and a method of inhibiting cancerous metastasis in a mammal are also provided.

Abstract: A .beta.1,6-N-acetylglucosaminyl transferase having the following properties:(1) Action: it transfers N-acetylglucosamine from UDP-N-acetylglucosamine to .alpha.-6-D-mannoside;(2) Substrate specificity: it shows a reactivity of about 79% for GnGnF-bi-PA, about 125% for GnGnGn-tri-PA and about 66% for GnM-Pa, when taking a reactivity for GnGn-bi-PA as 100%;(3) Optimum pH: 6.2 to 6.3;(4) Inhibition, Activation and Stability: Mn.sup.2+ is not necessary for expression of activity, and the activity is not inhibited in the presence of 20 mM EDTA;(5) Molecular weight: about 73,000 as determined by SDS-PAGE in the absence of reducing agent; and about 73,000 and about 60,000 as determined in the presence of a reducing agent;(6) Km value: 133 .mu.M and 3.

Abstract: An isolated DNA having a promoter activity in an animal cell; a method for expressing a useful gene using the isolated DNA; and a method for producing a protein in an animal cell using the isolated DNA. The present invention provides a method for producing a desired gene product in a large quantity in an animal cell.

Abstract: A .beta.1,6-N-acetylglucosaminyl transferase having the following properties:(1) Action: it transfers N-acetylglucosamine from UDP-N-acetylglucosamine to .alpha.-6-D-mannoside;(2) Substrate specificity: it shows a reactivity of about 79% for GnGnF-bi-PA, about 125% for GnGnGn-tri-PA and about 66% for GnM-Pa, when taking a reactivity for GnGn-bi-PA as 100%;(3) Optimum pH: 6.2 to 6.3;(4) Inhibition, Activation and Stability: Mn.sup.2+ is not necessary for expression of activity, and the activity is not inhibited in the presence of 20 mM EDTA;(5) Molecular weight: about 73,000 as determined by SDS-PAGE in the absence of reducing agent; and about 73,000 and about 60,000 as determined in the presence of a reducing agent;(6) Km value: 133 .mu.M and 3.5 mM for acceptor GnGn-bi-PA and donor UDP-GlcNAc, respectively; and(7) It includes the following peptide fragments:(SEQ ID NO.1) Thr-Pro-Trp-Gly-Lys(SEQ ID NO.2) Asn-Ile-Pro-Ser-Tyr-Val(SEQ ID NO.

Abstract: (+)-2-(2,4-Difluorophenyl)-3-methyl-1-(1H-1,2,4-triazol-1-yl)-3-(6-(1H-1,2, 4-triazol-1-yl)pyridazin-3-ylthio)butan-2-ol and a pharmaceutically acceptable salt thereof useful as an antifungal agent are disclosed. An inclusion complex of the compound with cyclodextrin can be given either orally or intravenously and has increased absorption when administered orally.

Abstract: This invention relates to a method of diagnosing cancerous diseases, which comprises measuring the amount of UDP-N-acetylglucosamine:glycoprotein N-acetylglucosaminyl-transferase in body fluid and evaluating the increase in its amount for the diagnosis of hepatic diseases.AFP, CEA and .gamma.-glutamyltranspeptidase have hitherto been used as tumor markers for the diagnosis of hepatic cancer. But these conventional tumor markers show a positivity rate of about 60%, making early diagnosis almost impossible.The method of this invention employs UDP-N-acetylglucosamine:glycoprotein N-acetylglucosaminyltransferase as tumor marker, whereby early diagnosis of hepatic cancer can be made almost completely.